HCV genotypes distribution in the Krasnoyarsk region HIV-positive and HIV-negative populations
Presented by Tatiana Chaychuk (Russian Federation).
T. Chaychuk1, N. Gankina1, O. Rumyanceva2, 1) HCV/HIV-co-infected patients and 2) HCV-infected patients without HIV co-infection
1Regional Center of AIDS Prevention, Medical Treatment Department, Krasnoyarsk, Russian Federation, 2Regional Center of AIDS Prevention, Laboratory of PCR Diagnostic, Krasnoyarsk, Russian Federation
Issues: HIV/HCV co-infections are highly prevalent in Krasnoyarsk region (approximately 50-60 percent). Due to the wide use of HAART and programs for prevention of opportunistic diseases, life expectancy of HIV-infected individuals has increased. Chronic viral hepatitis has become one of the principal causes of death. HIV/HCV co-infected patients and HIV-negative patients with HCV infection require HCV genotype testing.
Description: The HCV genotypes distribution in HIV-infected residents and in the patients without HIV co-infection of the Krasnoyarsk region were studied. We have investigated 623 blood samples taken from 623 HIV-positive patients and 1374 blood samples taken from 1374 HIV-negative patients by polymerase chain reaction method (PCR) using the "AmpliSens-50-R" test-system and the Bio-Rad Cycler Sample Loading Tray.
Lessons learned: HCV genotype 3 predominated in HIV-positive cohort samples (57.1%) and the rest were type 1 (39.5%) and type 2 with low distribution (3.4%). HCV genotype 3 was documented in HIV-negative cohort samples (36.2%), HCV genotype 1 predominated in this cohort's samples (57.7%), with type 2 being with low distribution (6%).
Next steps: In the Krasnoyarsk region, the distribution of HCV genotypes among HIV-infected individuals was observed with a higher prevalence of genotype 3 (57.1%) in comparison with the general population of Russia (10.5%). As has been shown in previous research, HCV genotype 3 is a favorable prognostic factor for achieving a sustained virologic response in most cases. HCV genotype 1 predominated in HIV-negative cohort patients (57.7%), which negatively affect the prognosis of treatment and of virusological response in this cohort. Our findings have potential implications for appropriate patient selection for HCV treatment, as individuals carrying this genotype are more likely to respond to therapy.
Download the e-Poster
Back to the session -
Back to the Programme-at-a-Glance